Autoimmune Diseases  >>  firategrast (SB683699)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
firategrast (SB683699) / GSK
NCT00097331: Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

Completed
2
261
Europe, RoW
SB683699
GlaxoSmithKline
Multiple Sclerosis, Relapsing-Remitting
07/06
07/06
NCT00469378 / 2006-007057-42: Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis

Checkmark Data
Oct 2010 - Oct 2010: Data
Completed
2
46
Europe
firategrast
GlaxoSmithKline
Multiple Sclerosis
05/09
02/10
NCT00395317 / 2006-002633-20: Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)

Checkmark Interim data
Oct 2010 - Oct 2010: Interim data
Completed
2
343
Canada, Europe, RoW
Placebo, Firategrast 150 mg, SB-683699, Firategrast 300 mg
GlaxoSmithKline
Multiple Sclerosis
08/09
08/10

Download Options